Macrogenics (MGNX) Revenue (2012 - 2026)
Macrogenics (MGNX) posted quarterly Revenue of $20.8 million for Q1 2026, up 57.48% year-over-year from $13.2 million in Q1 2025, and down 49.61% quarter-over-quarter from $41.2 million in Q4 2025.
Macrogenics (MGNX) Revenue (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Revenue for 15 consecutive years, with $20.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 57.48% year-over-year to $20.8 million; the TTM figure through Mar 2026 stood at $157.1 million (down 10.08% YoY), while the FY2025 annual figure was $149.5 million, changed 0.31% from the prior year.
- Revenue slipped to $20.8 million in Q1 2026 per MGNX's latest filing, from $41.2 million in the prior quarter.
- Across five years, Revenue topped out at $110.7 million in Q3 2024 and bottomed at $9.1 million in Q1 2024.
- Historically, Revenue has averaged $32.4 million across 5 years, with a median of $22.2 million in 2025.
- Annual changes were most pronounced in 2023 — Revenue slumped 85.33% — and 2024, when it surged 964.81%.
- Macrogenics' Revenue stood at $73.1 million in 2022, then plunged by 85.33% to $10.7 million in 2023, then soared by 273.13% to $40.0 million in 2024, then advanced by 3.07% to $41.2 million in 2025, then slumped by 49.61% to $20.8 million in 2026.
- Business Quant data shows MGNX's Revenue at $20.8 million in Q1 2026, $41.2 million in Q4 2025, and $72.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 20.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.78 Mn |
| Dec 31, 2025 | 41.23 Mn |
| Sep 30, 2025 | 72.84 Mn |
| Jun 30, 2025 | 22.24 Mn |
| Mar 31, 2025 | 13.19 Mn |
| Dec 31, 2024 | 40.00 Mn |
| Sep 30, 2024 | 110.71 Mn |
| Jun 30, 2024 | 10.80 Mn |
| Mar 31, 2024 | 9.10 Mn |
| Dec 31, 2023 | 10.72 Mn |
| Sep 30, 2023 | 10.40 Mn |
| Jun 30, 2023 | 13.14 Mn |
| Mar 31, 2023 | 24.50 Mn |
| Dec 31, 2022 | 73.10 Mn |
| Sep 30, 2022 | 41.73 Mn |
| Jun 30, 2022 | 26.01 Mn |
| Mar 31, 2022 | 11.10 Mn |
| Dec 31, 2021 | 14.15 Mn |
| Sep 30, 2021 | 15.66 Mn |
| Jun 30, 2021 | 30.76 Mn |